Physician profile
Noelle Soltero
NPI 1417585373
$912.78
in general payments reported to CMS, 2019-2025
16 companies · $36.05 in 2025
The $36.05 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $791 · 2022: $46.91 · 2023: $38.79 · 2025: $36.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.05 | 2021-2023 | |
| Daiichi Sankyo INC. | $136.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2021 | |
| Pharmacosmos Therapeutics INC. | $93.99 | 2021 | |
| Alexion Pharmaceuticals, INC. | $56.47 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.88 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $36.07 | 2021 | |
| Qol Medical, LLC | $28.07 | 2021 | |
| Pfizer INC. | $27.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.12 | 2021 | |
| Gilead Sciences, INC. | $20.81 | 2023 | |
| Redhill Biopharma INC. | $20.52 | 2021 | |
| Corcept Therapeutics | $19.66 | 2025 | Korlym |
| Amag Pharmaceuticals, INC. | $17.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.39 | 2025 | Airsupra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Soltero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.